Skip to content

Evaluation of the Effectiveness of a Protocol for the Management of Female Functional Urinary Signs

Evaluation of the Effectiveness of the Application of a Protocol for the Management of Female Functional Urinary Signs in French Community Pharmacies

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05510128
Acronym
PharmaCyst'
Enrollment
145
Registered
2022-08-22
Start date
2023-06-30
Completion date
2025-01-29
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystitis Acute

Brief summary

Every year, between 4 and 6 million French people are affected by a urinary infection; the vast majority of these are women. Although the diagnosis of an uncomplicated urinary tract infection is simple to make, it requires prompt medical management to relieve the symptoms. The lack of immediate of a physician can slow down the management of patients affected by this condition, and lead to an inappropriate referral of patients to the emergency services. Because of their wide availability, accessibility, and geographical distribution throughout the country, pharmacists are primary health care professionals who are regularly called upon to respond to patients with this type of infection. A national protocol exists in France, but it is very difficult to apply. The PharmaCyst' study aims to evaluate its application in community pharmacies.

Interventions

When a patient comes to the pharmacy with signs of urinary burning, the following will follow: * Completion of the acute cystitis symptoms score (ACSS) questionnaire. * Measure the temperature. * Perform a urine dipstick. If the patient's temperature is normal, the urine dipstick is positive, and the absence of pain in the lumbar fossa is verified, the pharmacist can dispense an appropriate antibiotic himself. A reminder of the hygienic-dietary rules is also issued, and a communication to the patient's general practitioner will be made.

Sponsors

University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Female * Age ≥ 18 and \<65 years * Patient with less than 3 days of simple urinary tract infection symptoms: * Burning, pain on urination * Dysuria * Pollakiuria * Urinary urgency * Patient affiliated or beneficiary of a social insurance * Patient having signed an informed consent.

Exclusion criteria

* More than 3 cystitis in the last 12 months; * Last cystitis less than 15 days old; * Presence of fever; * Presence of back pain; * Presence of a functional or organic anomaly of the urinary tract (bladder residue, vesico-ureteral reflux, lithiasis, tumor); * Pruritus or vaginal discharge; * Vomiting, diarrhea, diffuse abdominal pain; * Risk factors for C3G-resistant enterobacteria infection (grade B): * Exposure to an antibiotic (amoxicillin-clavulanic acid, C2G, C3G, fluoroquinolones) within the previous 3 months; * A nosocomial or healthcare-associated infection; * A history of colonization or infection with C3G-resistant enterobacteria within the last 3 months; * A trip to a foreign country within the last 3 months in known geographical areas at risk (in particular the Indian subcontinent, South-East Asia, the Middle East and North Africa, the Mediterranean basin); * Hospitalization within 3 months; * Hospitalization within 6 months for UTI; * Known severe renal insufficiency (creatinine clearance \< 30 mL/min); * Severe immunosuppression or immunosuppressive treatments; * Contraindications to drugs planned for experimental management (pivmecillinam and fosfomycin) or combination of drugs not recommended; * Pregnant women (confirmed or suspected pregnancy), breastfeeding women or women in labour; * Person deprived of liberty by judicial or administrative decision; * Person under forced psychiatric care; * Person admitted to a health or social institution for purposes other than research; * Person subject to a legal protection measure; * A person who is unable to give consent.

Design outcomes

Primary

MeasureTime frameDescription
The evolution of the symptoms at D3Enrollment, Day 3Difference in the score from the first part of the Acute Cystitis Symptome Score questionnaire. The minimum value is 0 and the maximun value is 18. A higher score mean worse outcome

Secondary

MeasureTime frameDescription
The evolution of the symptoms at D10Enrollment, Day 10Difference in the score from the first part of the Acute Cystitis Symptome Score questionnaire. The minimum value is 0 and the maximun value is 18. A higher score mean worse outcome
Use of a medical consultation or an emergency serviceAt 3 daysNumber of consultations provided
Performing a urine dipstickEnrollment, Day 3, Day 10Number of urine dipstick performed
Performing a urine cultureAt 3 days and 10 daysNumber of urine culture performed
Taking medication to relieve the symptoms of the infectionEnrollment,Number of medication used
Occurrence of an adverse event at D3 and D10At 10 daysNumber of adverse events
Recurrence of a urinary tract infection within 3 months (M3)At 3 monthsNumber of cystitis encountered

Countries

France

Contacts

PRINCIPAL_INVESTIGATORSébastien Faure, Professor

University of Angers

STUDY_DIRECTORAline Ramond-Roquin, Professor

University of Angers

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026